Acadia Pharmaceuticals Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing also reports fourth-quarter results. Acadia is a biopharmaceutical company focused on central nervous system disorders and rare diseases; its commercial products are NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and DAYBUE (trofinetide) for Rett syndrome. DAYBUE launched in the U.S. in April 2023.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change or context |
|---|---|---|---|
| Net product sales | $726.4 million | $517.2 million | Up 40.4%; included $177.2 million of DAYBUE sales, with no DAYBUE sales in 2022 |
| NUPLAZID sales | $549.2 million | $517.2 million | Up $32.0 million, attributed to unit growth and higher average net selling price |
| Gross profit | $684.8 million | $507.1 million | Gross margin was approximately 94.3%, versus 98.0% |
| Operating expenses | $799.8 million | $740.8 million | R&D: $351.6 million; SG&A: $406.6 million |
| Operating loss | $(73.4) million | $(223.6) million | Improved substantially year over year |
| Net loss | $(61.3) million | $(216.0) million | Loss per share: $(0.37), versus $(1.34) |
| Operating cash flow | $16.7 million | $(114.0) million | Turned positive |
| Cash, cash equivalents and investments | $438.9 million | $416.8 million | At December 31; management expects resources to fund planned operations through and beyond 12 months |
Fourth-quarter 2023 revenue was $231.0 million and gross profit was $213.2 million (about 92.3% gross margin), compared with $136.5 million and $134.1 million, respectively, in fourth-quarter 2022. Acadia reported fourth-quarter 2023 net income of $45.8 million, versus a net loss of $41.7 million a year earlier. The company reported a full-year net loss despite the fourth-quarter profit.
At year-end, current assets were $616.1 million and current liabilities were $254.3 million. The balance sheet lists $57.2 million of operating lease liabilities; the provided filing text does not identify funded borrowings or a debt balance. Total liabilities were $317.2 million. Operating cash flow improved partly with higher revenue and lower R&D spending, while growth in receivables, inventory and accrued liabilities affected working capital.
Material changes and notable items
- DAYBUE contributed $177.2 million of first-year U.S. sales following its 2023 launch, materially expanding the company’s commercial revenue base.
- SG&A increased to $406.6 million, primarily from DAYBUE launch costs; R&D declined to $351.6 million, mainly because less trofinetide commercial-supply build was expensed before approval.
- Cost of product sales rose to $41.6 million from $10.2 million. DAYBUE royalties and amortization contributed $21.8 million. Initial DAYBUE inventory had been expensed as R&D before approval; the company expects to finish selling this zero-cost inventory in 2024.
- Acadia paid Neuren a $100 million upfront amount in 2023 for expanded trofinetide rights and global rights to NNZ-2591; it also recorded a $40 million DAYBUE milestone and a $29.6 million estimated obligation relating to the priority review voucher. The filing states that potential future milestone payments across agreements could total up to $3.4 billion, contingent on development, regulatory and commercial achievements.
- The company sold its Neuren investment in 2023 for $12.3 million and recognized a $5.1 million gain.
Outlook, risks and contingencies
- Management expected top-line results from the Phase 3 ADVANCE-2 study of pimavanserin for negative symptoms of schizophrenia in the first quarter of 2024. This was an expectation stated in the filing, not a reported outcome.
- Acadia initiated Phase 3 COMPASS for ACP-101 in Prader-Willi syndrome and Phase 2 testing of ACP-204 for Alzheimer’s disease psychosis in late 2023. The filing provides no quantified revenue guidance in the text supplied.
- Management planned to pursue DAYBUE expansion: a Canadian submission was expected in early 2024, European regulatory engagement in early 2024 with an application targeted for the first half of 2025, and engagement with Japanese regulators during 2024.
- Key business risks include dependence on continued NUPLAZID and DAYBUE sales; product adoption, reimbursement and pricing pressure; clinical and regulatory uncertainty; reliance on contract manufacturers and concentrated distribution channels; and competition, patent challenges and potential generic entry.
- Several NUPLAZID patent disputes remained active. The filing reports a favorable January 2024 district-court judgment against MSN, which appealed; litigation involving MSN and Aurobindo also continued, with trial scheduled for December 2024. Hetero and Zydus settlements permit generic launches on specified future dates, subject to possible earlier-launch triggers.
- A securities class action and a derivative action related to prior disclosures concerning a pimavanserin application remained pending. Acadia stated it could not estimate possible losses and had not accrued amounts for these matters other than legal fees; management did not believe the claims were likely to have a material adverse effect, while noting litigation outcomes are uncertain.
- The filing identifies a cybersecurity incident at a drug-substance supplier in November 2023 that interrupted operations, and a prescription-processor cyberattack known as of February 21, 2024 that could affect payer authorizations for specialty-pharmacy prescriptions.
Important facts for investors to verify
- Subsequent DAYBUE sales, persistence, patient access and net pricing, alongside the trend in NUPLAZID sales.
- Reported results of ADVANCE-2 and any resulting regulatory or development plans for pimavanserin.
- DAYBUE launch economics as zero-cost inventory runs off, including royalties, manufacturing costs and gross margin.
- Cash burn, working-capital movements, and the timing and terms of contingent payments, royalties and lease obligations.
- Updates to NUPLAZID generic litigation, settlement launch dates and the securities and derivative cases.
- Regulatory progress and commercialization plans for DAYBUE outside the U.S., and clinical milestones for ACP-101 and ACP-204.